Folgen
Robert Shafer
Robert Shafer
Professor of Medicine, Stanford University
Bestätigte E-Mail-Adresse bei stanford.edu - Startseite
Titel
Zitiert von
Zitiert von
Jahr
2011 update of the drug resistance mutations in HIV-1
VA Johnson, V Calvez, HF Günthard, R Paredes, D Pillay, R Shafer, ...
Topics in antiviral medicine 19 (4), 156, 2011
12492011
Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update
DE Bennett, RJ Camacho, D Otelea, DR Kuritzkes, H Fleury, M Kiuchi, ...
PloS one 4 (3), e4724, 2009
11132009
The major genetic determinants of HIV-1 control affect HLA class I peptide presentation
International HIV Controllers Study
Science 330 (6010), 1551-1557, 2010
11092010
2017 update of the drug resistance mutations in HIV-1
AM Wensing, V Calvez, HF Günthard, VA Johnson, R Paredes, D Pillay, ...
Topics in antiviral medicine 24 (4), 132, 2016
10592016
Human immunodeficiency virus reverse transcriptase and protease sequence database
SY Rhee, MJ Gonzales, R Kantor, BJ Betts, J Ravela, RW Shafer
Nucleic acids research 31 (1), 298-303, 2003
10192003
The biological and clinical significance of emerging SARS-CoV-2 variants
K Tao, PL Tzou, J Nouhin, RK Gupta, T de Oliveira, SL Kosakovsky Pond, ...
Nature Reviews Genetics 22 (12), 757-773, 2021
9552021
Exogenous reinfection with multidrug-resistant Mycobacterium tuberculosis in patients with advanced HIV infection
PM Small, RW Shafer, PC Hopewell, SP Singh, MJ Murphy, ED Desmond, ...
New England Journal of Medicine 328 (16), 1137-1144, 1993
7731993
Web resources for HIV type 1 genotypic-resistance test interpretation
TF Liu, RW Shafer
Clinical infectious diseases 42 (11), 1608-1618, 2006
7162006
Characterization of mutation spectra with ultra-deep pyrosequencing: application to HIV-1 drug resistance
C Wang, Y Mitsuya, B Gharizadeh, M Ronaghi, RW Shafer
Genome research 17 (8), 1195-1201, 2007
5582007
HIV-1 antiretroviral resistance: scientific principles and clinical applications
MW Tang, RW Shafer
Drugs 72, e1-e25, 2012
4892012
Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection
GK Robbins, V De Gruttola, RW Shafer, LM Smeaton, SW Snyder, ...
New England Journal of Medicine 349 (24), 2293-2303, 2003
4732003
HIV-1 drug resistance mutations: an updated framework for the second decade of HAART
RW Shafer, JM Schapiro
AIDS reviews 10 (2), 67, 2008
4662008
Extrapulmonary tuberculosis in patients with human immunodeficiency virus infection
RW Shafer, DS Kim, JP Weiss, JM Quale
Medicine 70 (6), 384-397, 1991
4571991
Rationale and uses of a public HIV drug‐resistance database
RW Shafer
The Journal of infectious diseases 194 (Supplement_1), S51-S58, 2006
4522006
Genotypic testing for human immunodeficiency virus type 1 drug resistance
RW Shafer
Clinical microbiology reviews 15 (2), 247-277, 2002
4332002
HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance
RW Shafer, SY Rhee, D Pillay, V Miller, P Sandstrom, JM Schapiro, ...
Aids 21 (2), 215-223, 2007
4292007
Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaboration
R Kantor, DA Katzenstein, B Efron, AP Carvalho, B Wynhoven, P Cane, ...
PLoS medicine 2 (4), e112, 2005
3912005
HIV-1 drug resistance and resistance testing
DS Clutter, MR Jordan, S Bertagnolio, RW Shafer
Infection, Genetics and Evolution 46, 292-307, 2016
3382016
Genotypic predictors of human immunodeficiency virus type 1 drug resistance
SY Rhee, J Taylor, G Wadhera, A Ben-Hur, DL Brutlag, RW Shafer
Proceedings of the National Academy of Sciences 103 (46), 17355-17360, 2006
3382006
Update of the drug resistance mutations in HIV-1: March 2013
VA Johnson, V Calvez, HF Günthard, R Paredes, D Pillay, RW Shafer, ...
Topics in antiviral medicine 21 (1), 6, 2013
3232013
Das System kann den Vorgang jetzt nicht ausführen. Versuchen Sie es später erneut.
Artikel 1–20